Skip to main content

Clinical Trials Search

Tennessee Oncology is home to one of the leading clinical trial networks in the country. We offer a broad menu of trial opportunities in every phase of treatment. Use the search below to discover and learn more about our clinical trials:




51 Results

NCT03399799

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64407564,…

Condition: Multiple Myeloma
TO Study: MM 96
Phase: Phase 1
Clinic: Midtown Center for Blood Cancer, Tennessee Oncology Center for Blood Cancer
Protocol: 64407564MMY1001

View Details
NCT04830137

A Phase 1, Dose Escalation, Safety and Tolerability Study of…

Condition: Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Primary Central Nervous System Lymphoma, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia
TO Study: LYM 184
Phase: Phase 1
Clinic: Midtown Center for Blood Cancer, Tennessee Oncology Center for Blood Cancer
Protocol: NX-2127

View Details
NCT04756726

A Phase I/II Open-Label Multi-Center Study to Characterize the Safety…

Condition: Multiple Myeloma
TO Study: HR 68
Phase: Phase 1/2
Clinic: Tennessee Oncology Center for Blood Cancer, Midtown Center for Blood Cancer
Protocol: CFT7455-1101

View Details
NCT05722418

Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic…

Condition: Multiple Myeloma
TO Study: MM 161
Clinic: Midtown Center for Blood Cancer, Tennessee Oncology Center for Blood Cancer
Protocol: CB-011

View Details
NCT05651932

A Phase 1 Study of KTX-1001, an Oral, First-In-Class, Selective,…

Condition: Multiple Myeloma
TO Study: MM 159
Clinic: Tennessee Oncology Center for Blood Cancer, Midtown Center for Blood Cancer
Protocol: K36 MMSET-001

View Details
NCT05535244

A Phase I/II, Open-Label, Multi-Cohort Study to Evaluate the Efficacy…

Condition: Multiple Myeloma
TO Study: MM 155
Clinic: Midtown Center for Blood Cancer, Tennessee Oncology Center for Blood Cancer
Protocol: CO43476

View Details
NCT03915184

A Phase 1b/2, Open-label, Multi-center Trial to Evaluate the Safety…

Condition: Multiple Myeloma
TO Study: MM 142
Clinic: Midtown Center for Blood Cancer, Tennessee Oncology Center for Blood Cancer
Protocol: CT053-MM-02

View Details
NCT05950334

A Phase 1 Study of FT522 in Combination With Rituximab…

Condition: Large B-Cell Lymphoma
TO Study: LYM23002
Clinic: Midtown Center for Blood Cancer, Tennessee Oncology Center for Blood Cancer
Protocol: FT522-101

View Details
NCT05798897

A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen Specific T…

Condition: Chronic Lymphocytic Leukemia, Follicular Lymphoma, Hodgkin Lymphoma, Large B-Cell Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma
TO Study: LYM 211
Clinic: Midtown Center for Blood Cancer, Tennessee Oncology Center for Blood Cancer
Protocol: MRKR-22-601-01

View Details
NCT05605899

An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare…

Condition: Large B-Cell Lymphoma
TO Study: LYM 206
Clinic: Midtown Center for Blood Cancer, Tennessee Oncology Center for Blood Cancer
Protocol: KT-US-484-0136

View Details
NCT05371093

A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy…

Condition: Follicular Lymphoma
TO Study: LYM 202
Clinic: Midtown Center for Blood Cancer, Tennessee Oncology Center for Blood Cancer
Protocol: KT-US-473-0133

View Details
NCT03960840

Phase I/II, open label, multicenter study of rapcabtagene autoleucel in…

Condition: Acute lymphoblastic leukemia, Large B-Cell Lymphoma
TO Study: LYM 159
Clinic: Tennessee Oncology Center for Blood Cancer, Midtown Center for Blood Cancer
Protocol: CYTB323A12101

View Details
NCT05805501

A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in…

Condition: Renal Cell Carcinoma
TO Study: GU 215
Clinic: Cleveland, Downtown, MedPark 2, Memorial
Protocol: BO43936

View Details
NCT04657068

(EXPANSION) A Phase I/IIa, Open-label, Multi-center Study to Assess the…

(EXPANSION) A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally to Patients with Advanced or Metastatic Solid Tumors

Condition: Multiple Solid Tumors
TO Study: RM 721
Status: Open to Enrollment
Phase: Phase I/IIa
Clinic: Cleveland, Downtown, MedPark 2, Memorial
Protocol: ART0380C001

View Details
NCT04140526

Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single…

Condition: Multiple Solid Tumors
TO Study: MULTI 67
Status: Open to Enrollment
Phase: Phase IA/IB/II
Clinic: Cleveland, Downtown, MedPark 2, Memorial
Protocol: ONC-392-001

View Details
NCT04046445

An Open-Label, Multicenter, Non-Randomized, Dose-Confirmation and Cohort-Expansion Phase 1b Study…

Condition: Colorectal Cancer, Liver Metastasis Colon Cancer, Metastatic Colorectal Cancer, MSS, Stage IV Colon Cancer, Stage IV Rectal Cancer
TO Study:
Status: Open to Enrollment
Phase: Phase 1
Clinic: Chattanooga
Protocol: BI 754091

View Details
NCT05827016

Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide…

Condition: Multiple Myeloma
TO Study: MM 163
Status: Open to Enrollment
Phase: Phase 3
Clinic: Centennial Medical Center, Dickson, Franklin, Gallatin, Hendersonville, Lebanon, Midtown, Midtown Center for Blood Cancer, Murfreesboro, St. Thomas West, Shelbyville, Skyline, Smyrna, Southern Hills, Tennessee Oncology Center for Blood Cancer
Protocol: IM048022

View Details
NCT04975997

A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide,…

Condition: Multiple Myeloma
TO Study: MM 136
Status: Open to Enrollment
Phase: Phase 3
Clinic: Lebanon, Murfreesboro, Shelbyville, Summit, Midtown Center for Blood Cancer, Midtown, Centennial Medical Center, Gallatin, Tennessee Oncology Center for Blood Cancer
Protocol: CC-220- MM-002

View Details
NCT04270409

A Phase 3 Randomized, Open Label, Multicenter Study of Isatuximab…

Condition: Plasma Cell Myeloma
TO Study:
Status: Open to Enrollment
Phase: Phase 3
Clinic: Nashville
Protocol: EFC15992

View Details
NCT02343042

A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With…

Condition: Multiple Myeloma
TO Study:
Status: Open to Enrollment
Phase: Phase 1b/2
Clinic: Nashville
Protocol: KCP-330-017

View Details
NCT05688475

Continuing Treatment for Participants Who Have Participated in a Prior…

Condition: Non-Hodgkin Lymphoma
TO Study:
Status: Open to Enrollment
Phase: Phase 1
Clinic: Nashville
Protocol: CA0921000

View Details
NCT05207670

An Open-Label, Multicenter, Phase II Trial Evaluating the Safety, Efficacy,…

Condition: Non-Hodgkin Lymphoma
TO Study:
Status: Open to Enrollment
Phase: Phase 2
Clinic: Nashville, Chattanooga
Protocol: ML43389

View Details
NCT04014205

A Phase I/II，Multicenter, Open-Label, Study of a Novel Bruton’s Tyrosine…

Condition: B-cell Malignancies
TO Study:
Status: Open to Enrollment
Phase: Phase I/IIa
Clinic: Nashville
Protocol: ICP-CL-00107

View Details
NCT04561206

Brentuximab Vedotin and Nivolumab for the Treatment of Patients With…

Condition: Classical Hodgkin Lymphoma
TO Study: LYM 189
Status: Open to Enrollment
Phase: Phase 2
Clinic: Centennial Medical Center, Dickson, Franklin, Gallatin, Hendersonville, Lebanon, Midtown, Midtown Center for Blood Cancer, Murfreesboro, St. Thomas West, Shelbyville, Skyline, Smyrna, Southern Hills, Tennessee Oncology Center for Blood Cancer
Protocol: 20147

View Details
NCT04806035

A Phase 1b Multi-cohort Study of TG-1801 Alone or in Combination…

Condition: Aggressive Lymphoma, CLL, DLBCL, Follicular Lymphoma, Indolent Lymphoma, Marginal Zone Lymphoma, MCL, Mediastinal Large B-cell Lymphoma, Richter's Transformation, SLL
TO Study:
Status: Open to Enrollment
Phase: Phase 1b
Clinic: Nashville, Chattanooga
Protocol: TG-1801-102

View Details
NCT04824092

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the…

Condition: Diffuse Large B-Cell Lymphoma
TO Study:
Status: Open to Enrollment
Phase: Phase 3
Clinic: Nashville
Protocol: MOR208C310

View Details
NCT04464798

A Phase 1/2, Multicenter, Open-label Study to Assess Safety, Pharmacokinetics,…

Condition: Lymphoma
TO Study:
Status: Open to Enrollment
Phase: Phase 1/2
Clinic: Nashville
Protocol: CC-220-NHL-001

View Details
NCT04224493

Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive…

Condition: Follicular Lymphoma
TO Study: LYM 170
Status: Open to Enrollment
Phase: Phase 1b/3
Clinic: Centennial Medical Center, Dickson, Franklin, Gallatin, Hendersonville, Lebanon, Midtown, Midtown Center for Blood Cancer, Murfreesboro, St. Thomas West, Shelbyville, Skyline, Smyrna, Southern Hills, Tennessee Oncology Center for Blood Cancer
Protocol: EZH-302

View Details
NCT04170283

An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens…

Condition: B-cell Malignancies
TO Study:
Status: Open to Enrollment
Phase: Phase 3
Clinic: Nashville, Chattanooga
Protocol: BGB-3111-LTE1

View Details
NCT05091567

A Phase III, Randomized, Open-Label, Multicenter Study of Lurbinectedin in…

Condition: Small Cell Lung Cancer
TO Study:
Status: Open to Enrollment
Phase: Phase 3
Clinic: Chattanooga
Protocol: GO43104

View Details
NCT04984811

A Multicenter, Open-label, Single-arm Phase II Study to Evaluate Anti-tumor…

Condition: Non-small Cell Lung Cancer
TO Study: LUN 463
Status: Open to Enrollment
Phase: Phase 2
Clinic: Cleveland, Downtown, MedPark 2, Memorial
Protocol: NIT-119

View Details
NCT03739710

A Phase II, Randomized, Open-label Platform Trial Utilizing a Master…

Condition: Non-small Cell Lung Cancer
TO Study:
Status: Open to Enrollment
Phase: Phase 2
Clinic: Chattanooga
Protocol: GSK 205801

View Details
NCT05645692

A Phase II, Randomized, Multicenter, Open-Label, Controlled Study of Tobemstomig…

Condition: Urothelial Cancer
TO Study: GU 220
Status: Open to Enrollment
Phase: Phase 2
Clinic: Cleveland, Downtown, MedPark 2, Memorial
Protocol: BO44157

View Details
NCT05568095

A Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab,…

Condition: Esophageal Adenocarcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction
TO Study: GI 341
Status: Open to Enrollment
Phase: Phase 3
Clinic: Cleveland, Downtown, MedPark 2, Memorial
Protocol: STAR-221

View Details
NCT05425940

A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab…

Condition: Colorectal Cancer
TO Study: GI 344
Status: Open to Enrollment
Phase: Phase 3
Clinic: Cleveland, Downtown, MedPark 2, Memorial
Protocol: XL092-303

View Details
NCT04381832

Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based…

Condition: Androgen-Resistant Prostatic Neoplasms, Castration Resistant Prostatic Neoplasms, Castration-Resistant, Prostatic Cancer, Prostatic Neoplasms
TO Study:
Status: Open to Enrollment
Phase: Phase 1b/2
Clinic: Chattanooga
Protocol: ARC-6

View Details
NCT05348577

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as…

Condition: Prostate Cancer
TO Study: GU 209
Status: Open to Enrollment
Phase: Phase 3
Clinic: Cleveland, Downtown, MedPark 2, Memorial
Protocol: D361EC00001

View Details
NCT05288166

CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of…

Condition: Abiraterone Acetate and Hormone Antagonists, Androgens, Antineoplastic Agents, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Cytochrome P-450, Enzyme Inhibitors, Hormonal, Hormone Substitutes, Hormones, Neoplasm Metastasis, Physiological Effects of Drugs, Prednisolone, Prednisone, Prostatic Neoplasms, Steroid Synthesis Inhibitors, Urogenital Neoplasms
TO Study:
Status: Open to Enrollment
Phase: Phase 3
Clinic: Chattanooga
Protocol: I3Y-MC-JPEG

View Details
NCT05480306

Randomized Phase 2 Study of DKN-01 Plus FOLFIRI/FOLFOX and Bevacizumab…

Condition: Colorectal Cancer
TO Study: GI 340
Status: Open to Enrollment
Phase: Phase 2
Clinic: Cleveland, Downtown, MedPark 2, Memorial
Protocol: DEK-DKK1-P207

View Details
NCT03875235

A Phase III Randomized, Double-Blind Placebo Controlled, Multi-Regional, International Study…

Condition: Biliary Tract Cancer
TO Study: GI 286
Status: Open to Enrollment
Phase: Phase 3
Clinic: Cleveland, Downtown, MedPark 2, Memorial
Protocol: D933AC00001

View Details
NCT04471844

Pivotal, Randomized, Open-Label Study of Optune® (Tumor Treating Fields, 200kHz)…

Condition: Glioblastoma Multiforme
TO Study:
Status: Open to Enrollment
Phase: N/A
Clinic: Chattanooga
Protocol: Novocure_EF-32

View Details
NCT05254743

A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus…

Condition: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
TO Study: CLL 53
Status: Open to Enrollment
Phase: Phase 3
Clinic: Cleveland, Downtown, MedPark 2, Memorial
Protocol: LOXO-BTK-20030

View Details
NCT05057494

A Phase III Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib…

Condition: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
TO Study:
Status: Open to Enrollment
Phase: Phase 3
Clinic: Nashville
Protocol: D8220C00027

View Details
NCT04965493

A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib…

Condition: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
TO Study:
Status: Open to Enrollment
Phase: Phase 3
Clinic: Nashville, Chattanooga
Protocol: LOXO-BTK-20022

View Details
NCT04116437

A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in…

Condition: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia
TO Study: CLL 50
Status: Open to Enrollment
Phase: Phase 2
Clinic: Tennessee Oncology Center for Blood Cancer, Lebanon, Murfreesboro, Shelbyville, Summit, Midtown Center for Blood Cancer, St. Thomas West, Gallatin
Protocol: BGB-3111-215

View Details
NCT05645536

Open-label, Safety Extension Study for Subjects With HR+, HER2-Negative Breast…

Condition: Breast Cancer
TO Study:
Status: Open to Enrollment
Phase: Phase 3
Clinic: Chattanooga
Protocol: TOL2506A-EXT

View Details
NCT05629585

A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (DatoDXd)…

Condition: Triple Negative Breast Cancer
TO Study: BRE 409
Status: Open to Enrollment
Phase: Phase 3
Clinic: Cleveland, Downtown, MedPark 2, Memorial
Protocol: D926XC00001

View Details
NCT04468061

Saci-IO TNBC: Randomized Phase II Study of Sacituzumab Govitecan With…

Condition: Triple Negative Breast Cancer
TO Study: BRE 360
Status: Open to Enrollment
Phase: Phase 2
Clinic: Cleveland, Downtown, MedPark 2, Memorial
Protocol: 20-166

View Details
NCT05774951

A Phase III, Open-Label, Randomised Study to Assess the Efficacy…

Condition: HR+/HER2-Breast Cancer
TO Study: BRE 405
Status: Open to Enrollment
Phase: Phase 3
Clinic: Cleveland, Downtown, MedPark 2, Memorial
Protocol: D8531C00002

View Details
NCT04711252

SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833…

Condition: Breast Cancer
TO Study:
Status: Open to Enrollment
Phase: Phase 3
Clinic: Chattanooga
Protocol: D8532C00001

View Details
NCT04906395

Phase 3,Single Arm,Open-Label Study Evaluating Ovarian Suppression Following 3 Month…

Condition: HR+/HER2-Breast Cancer
TO Study: BRE 371
Status: Open to Enrollment
Phase: Phase 3
Clinic: Cleveland, Downtown, MedPark 2, Memorial
Protocol: TOL2506A

View Details